Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BMRN Stock Forecast 2025-2026
$58.01
Current Price
$11.11B
Market Cap
Buy 23
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to BMRN Price Targets
+110.3%
To High Target of $122.00
+63.8%
To Median Target of $95.00
+12.0%
To Low Target of $65.00
BMRN Price Momentum
-2.1%
1 Week Change
-6.3%
1 Month Change
-23.6%
1 Year Change
-11.7%
Year-to-Date Change
-38.8%
From 52W High of $94.85
+9.6%
From 52W Low of $52.93
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching BioMarin (BMRN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BMRN and similar high-potential opportunities.
Latest BMRN Stock Price Targets & Analyst Predictions
Based on our analysis of 42 Wall Street analysts, BMRN has a bullish consensus with a median price target of $95.00 (ranging from $65.00 to $122.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $58.01, the median forecast implies a 63.8% upside. This outlook is supported by 23 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Christopher Raymond at Piper Sandler, projecting a 110.3% upside. Conversely, the most conservative target is provided by Joel Beatty at Baird, suggesting a 12.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BMRN Analyst Ratings
23
Buy
6
Hold
0
Sell
BMRN Price Target Range
Low
$65.00
Average
$95.00
High
$122.00
Current: $58.01
Latest BMRN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BMRN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 5, 2025 | Goldman Sachs | Salveen Richter | Buy | Maintains | $104.00 |
| May 2, 2025 | Citigroup | David Lebovitz | Neutral | Maintains | $78.00 |
| Feb 24, 2025 | Oppenheimer | Leland Gershell | Outperform | Upgrade | $98.00 |
| Feb 20, 2025 | Citigroup | David Lebovitz | Neutral | Maintains | $82.00 |
| Feb 20, 2025 | UBS | Eliana Merle | Buy | Maintains | $113.00 |
| Feb 20, 2025 | RBC Capital | Luca Issi | Sector Perform | Reiterates | $70.00 |
| Feb 20, 2025 | B of A Securities | Geoff Meacham | Buy | Maintains | $103.00 |
| Feb 20, 2025 | Scotiabank | George Farmer | Sector Perform | Maintains | $80.00 |
| Feb 20, 2025 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $126.00 |
| Feb 20, 2025 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $90.00 |
| Dec 12, 2024 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $90.00 |
| Nov 15, 2024 | Wolfe Research | Akash Tewari | Outperform | Initiates | $95.00 |
| Oct 30, 2024 | JP Morgan | Jessica Fye | Overweight | Maintains | $109.00 |
| Oct 30, 2024 | William Blair | Tim Lugo | Market Perform | Downgrade | $0.00 |
| Oct 30, 2024 | Baird | Joel Beatty | Neutral | Maintains | $65.00 |
| Oct 30, 2024 | Evercore ISI Group | Cory Kasimov | Outperform | Maintains | $105.00 |
| Oct 30, 2024 | UBS | Eliana Merle | Buy | Maintains | $106.00 |
| Oct 30, 2024 | RBC Capital | Luca Issi | Sector Perform | Reiterates | $80.00 |
| Oct 30, 2024 | Canaccord Genuity | Whitney Ijem | Hold | Maintains | $84.00 |
| Oct 30, 2024 | Citigroup | David Lebovitz | Neutral | Maintains | $81.00 |
Biomarin Pharmaceutical Inc. (BMRN) Competitors
The following stocks are similar to BioMarin based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biomarin Pharmaceutical Inc. (BMRN) Financial Data
Biomarin Pharmaceutical Inc. has a market capitalization of $11.11B with a P/E ratio of 21.4x. The company generates $2.95B in trailing twelve-month revenue with a 17.8% profit margin.
Revenue growth is +14.8% quarter-over-quarter, while maintaining an operating margin of +30.0% and return on equity of +9.6%.
Valuation Metrics
Market Cap
$11.11B
Enterprise Value
$10.54B
P/E Ratio
21.4x
PEG Ratio
19.4x
Price/Sales
3.8x
Growth & Margins
Revenue Growth (YoY)
+14.8%
Gross Margin
+79.7%
Operating Margin
+30.0%
Net Margin
+17.8%
EPS Growth
+109.4%
Financial Health
Cash/Price Ratio
+11.4%
Current Ratio
5.5x
Debt/Equity
10.4x
ROE
+9.6%
ROA
+6.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Biomarin Pharmaceutical Inc. (BMRN) Business Model
About Biomarin Pharmaceutical Inc.
What They Do
Develops therapies for rare genetic diseases.
Business Model
BioMarin Pharmaceutical Inc. generates revenue through the development and commercialization of innovative therapies for rare genetic diseases. It has a diverse portfolio of eight approved medicines and a strong pipeline of clinical and preclinical candidates that address unmet medical needs, thereby creating significant market opportunities.
Additional Information
Founded in 1997 and headquartered in San Rafael, California, BioMarin operates in over 70 countries, with a notable presence across North America, Europe, Latin America, the Middle East, and Asia-Pacific. The company is recognized for its expertise in genetics and molecular biology, focusing on targeted treatments and maintaining dedicated manufacturing and research facilities.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
3,040
CEO
Mr. Alexander Hardy
Country
United States
IPO Year
1999
Website
www.biomarin.comBiomarin Pharmaceutical Inc. (BMRN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.
May 22, 2025
By Ekta Bagri
Analyst Blog
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
May 22, 2025
By Zacks Equity Research
Tale of the Tape
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
May 19, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Kahn Swick & Foti is investigating the proposed sale of Inozyme Pharma (INZY) to BioMarin Pharmaceutical (BMRN), where Inozyme shareholders would receive $4.00 per share.
Why It Matters
The investigation into Inozyme's sale to BioMarin may impact the stock's value, as potential legal issues could affect the deal's completion and shareholder returns.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
BMRN is acquiring INZY, adding a late-stage enzyme replacement therapy for a rare genetic condition, expected to close by September.
Why It Matters
BMRN's acquisition of INZY enhances its product portfolio with a late-stage therapy, potentially increasing revenue and market share in the rare disease sector, which can positively impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
BioMarin plans to acquire Inozyme Pharma for $270 million, resulting in a significant surge in Inozyme's share prices.
Why It Matters
BioMarin's $270 million acquisition of Inozyme Pharma indicates strategic growth and potential revenue increase, boosting Inozyme's market value significantly, which may attract further investor interest.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
BioMarin's acquisition includes INZ-701, a Phase 3 enzyme replacement therapy for ENPP1 deficiency, with pivotal data expected in early 2026 and potential launch in 2027. Conference call scheduled today at 8:45 a.m. ET.
Why It Matters
BioMarin's acquisition enhances its pipeline with a promising therapy for ENPP1 deficiency, potentially leading to significant revenue growth and market leadership in a niche segment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
BioMarin Pharmaceutical announced that VOXZOGO showed improvement in tibial bowing in children under 5 with achondroplasia. New studies indicate higher comorbidity rates in hypochondroplasia patients.
Why It Matters
Positive data on VOXZOGO's efficacy in treating achondroplasia could boost BioMarin's market position, potentially increasing demand and sales, impacting stock performance favorably.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores can assist investors in selecting strong, market-beating stocks for their portfolios.
Why It Matters
Zacks Style Scores can guide investors in identifying high-potential stocks, enhancing portfolio performance and potentially increasing returns in a competitive market.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About BMRN Stock
What is Biomarin Pharmaceutical Inc.'s (BMRN) stock forecast for 2025?
Based on our analysis of 42 Wall Street analysts, Biomarin Pharmaceutical Inc. (BMRN) has a median price target of $95.00. The highest price target is $122.00 and the lowest is $65.00.
Is BMRN stock a good investment in 2025?
According to current analyst ratings, BMRN has 23 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $58.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BMRN stock?
Wall Street analysts predict BMRN stock could reach $95.00 in the next 12 months. This represents a 63.8% increase from the current price of $58.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biomarin Pharmaceutical Inc.'s business model?
BioMarin Pharmaceutical Inc. generates revenue through the development and commercialization of innovative therapies for rare genetic diseases. It has a diverse portfolio of eight approved medicines and a strong pipeline of clinical and preclinical candidates that address unmet medical needs, thereby creating significant market opportunities.
What is the highest forecasted price for BMRN Biomarin Pharmaceutical Inc.?
The highest price target for BMRN is $122.00 from Christopher Raymond at Piper Sandler, which represents a 110.3% increase from the current price of $58.01.
What is the lowest forecasted price for BMRN Biomarin Pharmaceutical Inc.?
The lowest price target for BMRN is $65.00 from Joel Beatty at Baird, which represents a 12.0% increase from the current price of $58.01.
What is the overall BMRN consensus from analysts for Biomarin Pharmaceutical Inc.?
The overall analyst consensus for BMRN is bullish. Out of 42 Wall Street analysts, 23 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $95.00.
How accurate are BMRN stock price projections?
Stock price projections, including those for Biomarin Pharmaceutical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 2:21 AM UTC